Liraglutide CAS NO.204656-20-2

Lilarubicin, as a new long-acting GLP-1 analog, has 97% sequence homology with human GLP-1. Human GLP-1 can bind to and activate GLP-1 receptor. GLP-1 receptor is a target of natural GLP-1. GLP-1 receptor is an endogenous intestinal insulin-stimulating hormone, which can promote the proliferation and differentiation of islet β cells and significantly protect and improve the function of islet β cells. At the same time, Lilarubicin is simple and convenient to use, can provide 24 hours blood glucose control once a day, and the risk of hypoglycemia is small, so it is expected to become a new drug for the treatment of type 2 diabetes mellitus.

Lilaruin is a revolutionary drug in the treatment of type 2 diabetes mellitus. It is suitable for type 2 diabetic patients whose blood glucose is still not well controlled after metformin or sulfonylurea alone. It adjusts blood glucose in a concentration-dependent manner, directly protects B cells, increases insulin secretion and reduces improper glucagon secretion by a cell, and reduces body weight by increasing satiety and reducing calorie intake. Reduce systolic blood pressure, the sooner the application, the better.

Adverse reactions: the incidence of hypoglycemia is very low during the treatment of Lilarupeptide. Gastrointestinal discomfort is the most common adverse reaction in the treatment of Lilarupeptide. Slowly increasing the dose of Lilarupeptide can reduce the incidence of dose-related nausea. Gastrointestinal discomfort was common in the first week of Lilaruzin treatment. Diarrhea and nausea occurred most frequently, most of which were transient, mild or tolerable, and were related to the dose of Lilarupeptide.